Breaking News Instant updates and real-time market news.

SNBR

Sleep Number

$36.75

-0.29 (-0.78%)

, CLD

Cloud Peak

$4.28

0.08 (1.90%)

17:22
02/15/18
02/15
17:22
02/15/18
17:22

On The Fly: After Hours Movers

UP AFTER EARNINGS: Sleep Number (SNBR), up 9.1%... Cloud Peak Energy (CLD), up 6.3%... Andeavor (ANDV), up 1.9%... Kimco Realty (KIM), up 1.9%... SS&C Technologies (SSNC), up 1.8%... DDR Corp. (DDR), up 1.4%. ALSO HIGHER: Tandem Diabetes (TNDM), up 7.9% after it and Rubin Medical reached an agreement for the distribution of insulin pump products in Scandinavia. DOWN AFTER EARNINGS: Cohu (COHU), down 17%... Arista Networks (ANET), down 16.5%... Cognex (CGNX), down 10.2%... Impinj (PI), down 9.3%... Allscripts (MDRX), down 9.2%... TrueCar (TRUE), down 5%... Flowserve (FLS), down 4.1%... Shake Shack (SHAK), down 2.4%. ALSO LOWER: Nano Dimension (NNDM), down 32.6% after it announced an ADS offering.

SNBR

Sleep Number

$36.75

-0.29 (-0.78%)

CLD

Cloud Peak

$4.28

0.08 (1.90%)

ANDV

Andeavor

$99.07

0.46 (0.47%)

KIM

Kimco Realty

$14.67

0.41 (2.88%)

SSNC

SS&C

$50.28

0.52 (1.05%)

DDR

DDR Corp.

$7.40

0.21 (2.92%)

TNDM

TNDM

COHU

Cohu

$22.92

0.87 (3.95%)

ANET

Arista Networks

$307.96

5.84 (1.93%)

CGNX

Cognex

$58.80

0.75 (1.29%)

PI

Impinj

$13.43

0.52 (4.03%)

MDRX

Allscripts

$14.84

0.39 (2.70%)

TRUE

TrueCar

$11.91

0.66 (5.87%)

FLS

Flowserve

$42.87

0.68 (1.61%)

SHAK

Shake Shack

$41.21

1.57 (3.96%)

NNDM

Nano Dimension

$3.29

0.226 (7.38%)

  • 15

    Feb

  • 15

    Feb

  • 15

    Feb

  • 15

    Feb

  • 15

    Feb

  • 15

    Feb

  • 15

    Feb

  • 15

    Feb

  • 15

    Feb

  • 15

    Feb

  • 15

    Feb

  • 16

    Feb

  • 16

    Feb

  • 22

    Feb

  • 22

    Feb

  • 26

    Feb

  • 26

    Feb

  • 26

    Feb

  • 01

    Mar

  • 06

    Mar

  • 06

    Mar

  • 07

    Mar

  • 08

    Mar

  • 13

    Mar

  • 14

    Mar

  • 29

    Mar

  • 30

    May

SNBR Sleep Number
$36.75

-0.29 (-0.78%)

11/27/17
WEDB
11/27/17
NO CHANGE
WEDB
Black Friday promotions ratchet higher, says Wedbush
Wedbush analyst Seth Basham notes that as holiday shopping continues to shift online to the detriment of many brick and mortar retailers, Black Friday promotions in home furnishings and home improvements ratcheted higher this year at most retailers under his coverage. Based on his detailed analysis, the analyst found more aggressive promotions from Bed Bath & Beyond (BBBY), Pier 1 Imports (PIR), Wayfair (W), Home Depot (HD), Lowe's (LOW) and Sleep Number (SNBR). The analyst also points out that he leans positive on Wayfair and Williams-Sonoma (WSM).
12/06/17
STFL
12/06/17
NO CHANGE
STFL
Stifel says Steinhoff news may be good for Tempur Sealy, bad for Leggett & Platt
Stifel analyst John Baugh noted that Steinhoff shares are down more than 60% in Frankfurt after its CEO resigned amid an investigation into irregular accounting practices. He believes the news could benefit Tempur Sealy (TPX), a sales competitor to Steinhoff's Mattress Firm, and could also benefit Sleep Number (SNBR) to a lesser extent. Baugh also thinks this could be bad news for Leggett & Platt (LEG), which has Steinhoff as an important customer.
11/03/17
BOFA
11/03/17
DOWNGRADE
BOFA
Underperform
Sleep Number downgraded to Underperform from Neutral at BofA/Merrill
CLD Cloud Peak
$4.28

0.08 (1.90%)

03/07/17
JEFF
03/07/17
INITIATION
Target $5
JEFF
Hold
Cloud Peak initiated with a Hold at Jefferies
Jefferies analyst Christopher LaFemina started Cloud Peak Energy with a Hold rating and $5 price target. The analyst views the current valuation as high.
03/23/17
03/23/17
UPGRADE
Target $4

Market Perform
Cloud Peak upgraded to Market Perform from Underperform at FBR Capital
FBR Capital analyst Lucas Pipes upgraded Cloud Peak Energy to Market Perform and lowered his price target for the shares to $4 from $5.
11/20/17
JPMS
11/20/17
DOWNGRADE
JPMS
Neutral
Cloud Peak downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst John Bridges downgraded Cloud Peak Energy (CLD) to Neutral citing valuation following the recent outperformance of the shares. The analyst does not have a price target for the stock. He believes thermal producers Alliance Resource Partners (ARLP) and Cloud Peak "need better coal prices to shine."
ANDV Andeavor
$99.07

0.46 (0.47%)

02/14/18
SBSH
02/14/18
UPGRADE
Target $132
SBSH
Buy
Andeavor upgraded to Buy from Neutral at Citi
Citi analyst Prashant Rao upgraded Andeavor to Buy after taking over coverage of the name. The analyst sees an "execution/growth story with the best risk/return profile of the group." He names Andeavor his top pick in North American Refiners. Rao raised his price target for the shares to $132 from $126.
01/22/18
SBSH
01/22/18
INITIATION
Target $126
SBSH
Neutral
Andeavor resumed with a Neutral at Citi
Citi analyst Faisel Khan resumed coverage of Andeavor with a Neutral rating and $126 price target. The analyst believes the valuation currently reflects the company's "strong fundamental outlook."
12/06/17
WELS
12/06/17
NO CHANGE
Target $141
WELS
Outperform
Andeavor price target raised to $141 from $127 at Wells Fargo
Wells Fargo analyst Roger Read raised his price target for Andeavor to $141 and says the shares remain his top pick following the company's analyst day. Andeavor expects "meaningful" EBITDA growth across all three segments and plans to grow its dividend with the growth of the company, Read told investors earlier in a research note. He raised his estimates for the company and keeps an Outperform rating on the name.
01/03/18
FBCO
01/03/18
INITIATION
Target $142
FBCO
Outperform
Andeavor initiated with an Outperform at Credit Suisse
Credit Suisse analyst Kristina Kazarian started Andeavor with an Outperform rating and $142 price target as she expects EBITDA to grow 40%-45% over the next 3 years, driven by strategic refining projects that improve margins, midstream expansions that increase access to advantaged crude and add stable 3rd party-sourced cash flows, and marketing growth that supports refining through higher offtake capacity.
KIM Kimco Realty
$14.67

0.41 (2.88%)

09/26/17
JPMS
09/26/17
UPGRADE
Target $24
JPMS
Overweight
Kimco Realty upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Michael Mueller upgraded Kimco Realty to Overweight with an unchanged price target of $24. Retail trends are beginning to improve and the shares trade at an attractive valuation, the analyst contends.
11/30/17
STFL
11/30/17
INITIATION
STFL
Hold
Kimco Realty resumed with a Hold at Stifel
Stifel resumed coverage of Kimco Realty with a Hold rating and $19.50 price target.
11/27/17
BARD
11/27/17
DOWNGRADE
Target $20
BARD
Neutral
Kimco Realty downgraded to Neutral from Outperform at Baird
Baird analyst RJ Milligan downgraded Kimco Realty to Neutral and lowered his price target for the shares to $20 from $23. To reflect increased disposition assumptions, the analyst lowered his 2018 FFO estimate for Kimco by 7% to $1.51. He finds it difficult to see how the shares outperform peers with $700M of development/redevelopment projects expected over the next two years.
12/15/17
JPMS
12/15/17
DOWNGRADE
Target $20
JPMS
Neutral
Kimco Realty downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Anthony Paolone downgraded Kimco Realty to Neutral and lowered his price target for the shares to $20 from $22 in conjunction with his 2018 REIT outlook.
SSNC SS&C
$50.28

0.52 (1.05%)

01/12/18
DADA
01/12/18
DOWNGRADE
Target $84
DADA
Neutral
DST Systems downgraded to Neutral at DA Davidson on SS&C deal
As noted earlier, DA Davidson analyst Peter Heckmann downgraded DST Systems (DST) to Neutral from Buy and raised his price target to $84 from $72. Heckmann cites the company's acquisition by SS&C (SSNC) at $84 per share and believes that shareholder got a good outcome in the deal, estimating the probability of a competitive bid to be "quite low".
01/12/18
EVER
01/12/18
DOWNGRADE
Target $83
EVER
In Line
DST Systems downgraded to In Line from Outperform at Evercore ISI
Evercore ISI analyst David Togut downgraded DST Systems (DST) to In Line with an $83 price target following the company's agreement to be acquired by SS&C Technologies (SSNC).
01/16/18
WBLR
01/16/18
DOWNGRADE
WBLR
Market Perform
SS&C downgraded to Market Perform from Outperform at William Blair
William Blair analyst Christopher Shutler downgraded SS&C Technologies (SSNC) to Market Perform saying the risk/reward is more balanced following the rally in the shares post the DST Systems (DST) acquisition announcement.
01/17/18
BARD
01/17/18
DOWNGRADE
BARD
Neutral
DST Systems downgraded to Neutral from Outperform at Baird
Baird analyst David Koning downgraded DST Systems (DST) to Neutral following the company's agreement to be acquired by SS&C Technologies (SSNC).
DDR DDR Corp.
$7.40

0.21 (2.92%)

12/04/17
EVER
12/04/17
DOWNGRADE
EVER
In Line
DDR Corp. downgraded to In Line from Outperform at Evercore ISI
11/30/17
STFL
11/30/17
INITIATION
Target $8.25
STFL
Hold
DDR Corp. initiated with a Hold at Stifel
Stifel started DDR Corp. with a Hold rating and $8.25 price target.
12/19/17
KEYB
12/19/17
DOWNGRADE
KEYB
Sector Weight
DDR Corp. downgraded to Sector Weight from Overweight at KeyBanc
KeyBanc analyst Jordan Sadler downgraded DDR Corp to Sector Weight, saying the REIT is likely to perform comparably to its peers in the near term despite the spin-off of 50 assets which he views to be a positive. Sadler says the REIT's valuation already reflects a challenging environment, but sees uncertainty regarding any potential improvement in the near term.
12/15/17
SBSH
12/15/17
NO CHANGE
Target $11
SBSH
Buy
DDR Corp. a more attractive takeover candidate after spinoff, says Citi
Citi analyst Michael Bilerman said he likes DDR Corp.'s (DDR) plan to spin off assets into a new REIT to be called Retail Value Trust, arguing that the "new DDR" assets are likely worth close to $10-$11 per share and the RVT assets are reasonably worth $2-$3 per share. Given that valuation view, the RVT spin-co assets are essentially "free" to investors, said Bilerman. Additionally, "new DDR" will become a "much more attractive" acquisition candidate with the RVT assets remove, said Bilerman, who keeps a Buy rating on DDR shares.
TNDM TNDM

01/18/18
PIPR
01/18/18
NO CHANGE
Target $82
PIPR
Overweight
Insulet is a favored diabetes play on business momentum, says Piper Jaffray
Piper Jaffray analyst JP McKim says he hosted calls yesterday with two Certified Diabetes Educators from a "high volume center" and learned that they expect Continuous Glucose Monitoring - CGM - to become a "standard of care" in the Type 1 market, which can reach penetration of 85% vs 40% today. The analyst says the findings support his view that CGM is set for accelerating growth. Kim also notes that the impact on Medtronic (MDT) is improving, while the business momentum at Insulet (PODD) continues. The analyst rates Insulet as his top choice, followed by Dexcom (DXCM) and Tandem Diabetes Care (TNDM) in the space, given the headline risk around Libre coverage and insufficient evidence of accelerating pump additions for the latter names respectively. Kim keeps his Overweight rating and $82 price target on Insulet.
02/15/18
PIPR
02/15/18
NO CHANGE
PIPR
Tandem's financing, study data both positive signs, says Piper Jaffray
Piper Jaffray analyst JP McKim said he is becoming more positive on Tandem Diabetes since its most recent round of financing removes its liquidity risk, and its PROLOG study data showed a 31% reduction in hypo readings without increasing hyper readings. However McKim maintained a Neutral rating on Tandem Diabetes shares, saying he needs to see another quarter of solid pump sales to become more constructive on the stock.
11/21/17
PIPR
11/21/17
NO CHANGE
PIPR
Piper says selection for Lilly 'diabetes ecosystem' a clear positive for Dexcom
Piper Jaffray analyst Matt O'Brien said it was news to him that Eli Lilly (LLY) is developing a diabetes pump and smart pen as part of its "diabetes ecosystem" plans. The company's selection of Dexcom's (DXCM) CGM as part of their integrated system is a clear positive for Dexcom, while Lilly's launch of an integrated system in the U.S. market is a modest negative for Insulet (PODD) and Tandem Diabetes (TNDM) given it will create a competitive headwind starting in 2021, added O'Brien.
10/10/17
WEDB
10/10/17
NO CHANGE
Target $17
WEDB
Outperform
Tandem Diabetes price target lowered to $17 from $50 at Wedbush
Wedbush analyst Tao Levy lowered his price target for Tandem Diabetes to $17 from $50 to reflect the risk of further dilution as it seeks to improve its cash position. He reiterates an Outperform rating on the shares.
COHU Cohu
$22.92

0.87 (3.95%)

05/01/17
NEED
05/01/17
NO CHANGE
Target $15
NEED
Buy
Needham remains a buyer of FormFactor ahead of Q1 results
Needham analyst Y. Edwin Mok recommends investors buy FormFactor (FORM) going into the Q1 report. The analyst notes that reports by Teradyne (TER) and Cohu (COHU) give him more confidence on FormFactor's outlook and upside to Q2 revenue estimate. Mok believes a strong Q1 would bring investors back into the name and therefore reiterates a Buy rating and $15 price target on FormFactor's shares.
09/18/17
NEED
09/18/17
UPGRADE
NEED
Buy
Cohu upgraded to Buy from Hold at Needham
09/18/17
NEED
09/18/17
UPGRADE
NEED
Buy
Cohu upgraded on strong auto business at Needham
As noted earlier, Needham upgraded Cohu to Buy from Hold, Analyst Y. Edwin Mok says that the company has more exposure to the growing auto infotainment and cluster, or IC, business than any other name he covers. He is confident that the company's revenue will grow at a "solid" rate "in 2018 and beyond," driven by share gains and new products." Mok estimates that its EPS can reach roughly $2.50 over the longer term. Target $24.
ANET Arista Networks
$307.96

5.84 (1.93%)

02/07/18
GSCO
02/07/18
INITIATION
Target $320
GSCO
Conviction Buy
Arista Networks initiated with a Conviction Buy at Goldman Sachs
Goldman analyst Rod Hall initiated Arista Networks with a Conviction Buy and $320 price target. Hall said Arista's premium valuation is supported by strong secular growth in the greater than100G data center switching market combined with execution. The analyst differs with consensus on R&D intensity forecasting 2018 R&D/Sales of 16.4% versus consensus of 18.2%. This note corrects our previous note that said shares were initiated with a Buy rating.
02/14/18
PIPR
02/14/18
NO CHANGE
Target $230
PIPR
Neutral
Arista more likely to win 945 case after key win from appeals board, says Piper Jaffray
Piper Jaffray analyst James Fish notes that Arista Networks (ANET) received a "key win" in the 945 case against Cisco (CSCO), as the Federal Appeals Court found the 668 patent as un-patentable. This leaves less "ammo" for Cisco to win in the 945 case and increases the probability of an Arista win, he contends. The analyst believes this recent development was already expected to go in Arista's favor given the past few rulings as it related to the 668 patent. Fish reiterates a Neutral rating and $230 price target on Arista's shares.
02/06/18
GSCO
02/06/18
INITIATION
Target $320
GSCO
Buy
Arista Networks initiated with a Buy at Goldman Sachs
Goldman analyst Rod Hall initiated Arista Networks with a Buy and $320 price target. Hall said Arista's premium valuation is supported by strong secular growth in the greater than100G data center switching market combined with execution. The analyst differs with consensus on R&D intensity forecasting 2018 R&D/Sales of 16.4% versus consensus of 18.2%
02/13/18
RBCM
02/13/18
NO CHANGE
Target $310
RBCM
Outperform
Arista Networks price target raised to $310 from $234 at RBC Capital
RBC Capital analyst Mitch Steves raised his price target on Arista Networks (ANET) to $310, saying that the recent multiple expansion suggests that expectations are firming for a "notable beat and raise" on Q4 earnings. The analyst believes that operating margins will become a focal point for the company going forward, adding that the weakness in Juniper's (JNPR) quarter implies market share gains in the Data Center space. Steves also expects Arista competition with Cisco (CSCO) to tighten as the former takes up more market in Hyperscale while the latter protects is core enterprise business. The analyst keeps his Outperform rating on Arista Networks.
CGNX Cognex
$58.80

0.75 (1.29%)

08/14/17
WOLF
08/14/17
UPGRADE
WOLF
Outperform
Cognex upgraded to Outperform from Peer Perform at Wolfe Research
12/08/17
DAIW
12/08/17
UPGRADE
DAIW
Buy
Cognex upgraded to Buy from Outperform at Daiwa
01/19/18
DBAB
01/19/18
INITIATION
Target $80
DBAB
Buy
Cognex resumed with a Buy at Deutsche Bank
Deutsche Bank analyst Karen Lau resumed coverage of Cognex with a Buy rating and $80 price target. The analyst believes the company is favorably positioned as a focused play on the secular automation theme.
11/08/17
JPMS
11/08/17
DOWNGRADE
Target $125
JPMS
Underweight
Cognex downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Paul Coster downgraded Cognex to Underweight with an unchanged price target of $125 citing valuation. The analyst recommends using the recent strength in the shares as a selling opportunity.
PI Impinj
$13.43

0.52 (4.03%)

02/02/18
ADAM
02/02/18
DOWNGRADE
Target $20
ADAM
Hold
Impinj downgraded to Hold at Canaccord
As previously reported, Canaccord analyst T. Michael Walkley downgraded Impinj to Hold from Buy. The analyst noted the company lowered guidance for Q2 due to delayed rollouts and increased competitive price pressures. He now has less confidence in the company's growth potential over the next several quarters given the deteriorating business trends. Walkley lowered his price target to $20 from $35 on Impinj shares.
02/02/18
NEED
02/02/18
DOWNGRADE
NEED
Hold
Impinj downgraded to Hold at Needham on soft Q1 outlook
As reported earlier, Needham analyst James Ricchiuti downgraded Impinj to Hold from Buy after a "double blow" to investors with a 31-37% decline in expected Q1 revenues and the resignation of the company CFO who has been with the company since 2001. The analyst believes the Impinj challenges coming at a time when RFID market is healthy signals company-specific issues that could lead to market share losses. Ricchiuti warns that despite the big drop in the stock price, a recovery to Impinj business may not materialize until 2019.
02/06/18
PIPR
02/06/18
UPGRADE
Target $18
PIPR
Overweight
Impinj upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray analyst Troy Jensen upgraded Impinj to Overweight while maintaining an $18 price target for the shares. The recent sell-off in the stock has created a "compelling" valuation, Jensen tells investors in a research note. The analyst believes the company's "poor" March quarter guidance was amplified by Impinj's investment in finished goods inventory, which he notes is reducing lead-times and allowing partners to lower inventory levels.
02/02/18
02/02/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Apple (AAPL) was downgraded to Market Perform from Outperform at Bernstein and to Sector Weight from Overweight at KeyBanc. 2. Alphabet (GOOG, GOOGL) downgraded to Hold from Buy at Stifel with analyst Scott Devitt citing fourth quarter results and saying he has some longer-term concerns around competition from Amazon (AMZN), Google Cloud Platform market share, regulatory risk and rising traffic acquisition cost. 3. Hershey (HSY) downgraded to Neutral from Outperform at Credit Suisse with analyst Robert Moskow saying the stock deserves a "more narrow" valuation premium to food peers than in the past due to the deceleration of its growth rate and the stagnation of its profit margin. 4. Impinj (PI) was downgraded to Neutral from Buy at Dougherty, to Hold from Buy at Needham and Canaccord, and to Sector Perform from Outperform at RBC Capital. 5. Tractor Supply (TSCO) downgraded to Underperform from Buy at BofA/Merrill with analyst Elizabeth Suzuki saying the fourth quarter results were strong, but the outlook for 2018 was disappointing as management outlined expectations for operating margin compression and a store growth trajectory. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
MDRX Allscripts
$14.84

0.39 (2.70%)

01/29/18
CANT
01/29/18
NO CHANGE
Target $17
CANT
Overweight
Allscripts has good understanding of Practice Fusion investigation, says Cantor
Cantor Fitzgerald analyst Steven Halper notes a FierceHealthcare.com article last week suggested that an ongoing Department of Justice investigation had affected the purchase price paid by the company for Practice Fusion. Given the terms of the acquisition, Allscripts will inherit any potential liability that arises from the investigation, Halper tells investors in a research note. He believes, however, that Allscripts management has a good understanding of the issue and is comfortable with Practice Fusion's legal position. Allscripts can absorb any "reasonable monetary settlement if that is the outcome," Halper adds. He reiterates an Overweight rating on the shares with a $17 price target.
01/16/18
RHCO
01/16/18
DOWNGRADE
Target $16
RHCO
Hold
Allscripts downgraded to Hold at SunTrust on valuation
As reported earlier, SunTrust analyst Sandy Draper downgraded Allscripts to Hold from Buy with a $16 price target. Draper says that while he is not changing his outlook on the company, the 43% run-up in the stock price in 2017 and PE multiple approaching a 2-year high warrants a rating change, as shares are now likely to be "fully valued". The analyst adds that 2018 may prove to be difficult for bookings relative to 2017, and that the Street consensus of FY18 EPS may be over-estimating cost-cutting.
01/16/18
RHCO
01/16/18
DOWNGRADE
RHCO
Hold
Allscripts downgraded to Hold from Buy at SunTrust
TRUE TrueCar
$11.91

0.66 (5.87%)

10/02/17
MSCO
10/02/17
UPGRADE
Target $13
MSCO
Equal Weight
TrueCar upgraded to Equal Weight from Underweight at Morgan Stanley
Morgan Stanley analyst Brian Nowak upgraded TrueCar to Equal Weight from Underweight, as he believes the stock now trades at an appropriate valuation following the pullback after its Q2 results and guidance missed expectations. Nowak keeps a $13 price target on TrueCar shares.
11/07/17
JMPS
11/07/17
NO CHANGE
Target $19
JMPS
Outperform
TrueCar issue at USAA fixable, says JMP Securities
JMP Securities analyst Ronald Josey attributed TrueCar's Q3 revenue miss and Q4 revenue guidance shortfall to a change in the USAA car-buying experience driving a decline in cars sold. While USAA is a near-term headwind, Josey views the USAA issue as fixable, he tells investors in a post-earnings research note. Josey lowered his price target on TrueCar shares to $19 from $23 but keeps an Outperform rating on the stock, citing the upcoming catalysts of OEM incentives and TrueTrade.
11/07/17
RBCM
11/07/17
NO CHANGE
Target $18
RBCM
Outperform
TrueCar price target lowered to $18 from $23 at RBC Capital
RBC Capital analyst Mark Mahaney lowered his price target on TrueCar to $18 following a Q3 revenue miss and a lower FY17 outlook. Mahaney says the company suffered from poor performance at its USAA channel, while operating expenditures also showed greater leverage than expected. The analyst keeps his Outperform rating, saying the company is working to address the USAA issues which were related to negative user traffic impact from its recently updated website. Mahaney adds that the company can benefit from the FY18 ramp of new products and initiatives.
10/11/17
GSCO
10/11/17
INITIATION
Target $17
GSCO
Neutral
TrueCar assumed with a Neutral at Goldman Sachs
Goldman analyst Christopher Merwin assumed coverage on TrueCar with a Neutral and $17 price target saying he would like to see traffic accelerate in order to become more positive on shares.
FLS Flowserve
$42.87

0.68 (1.61%)

12/11/17
12/11/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Kimberly-Clark (KMB) downgraded to Sell from Neutral at Citi with analyst Wendy Nicholson citing "stiff competition" Kimberly-Clark faces "in multiple categories in multiple markets." 2. TSYS (TSS) downgraded to Neutral from Buy at Goldman Sachs with analyst James Schneider citing valuation with the shares approaching his unchanged price target of $80. 3. Paccar (PCAR) downgraded to Neutral from Overweight at JPMorgan with analyst Ann Duignan saying the North American Class 8 truck market is likely to peak in 2018 and Paccar's stock is likely to continue to see multiple compression. 4. Flowserve (FLS) downgraded to Hold from Buy at Stifel with analyst Nathan Jones saying he sees no near-term catalysts given his expectation of orders being flat to down in the fourth quarter. 5. Brixmor (BRX) downgraded to Neutral from Buy at Mizuho. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/07/17
GSCO
12/07/17
DOWNGRADE
GSCO
Sell
Flowserve downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs analyst Joseph Ritchie downgraded Flowserve (FLS) to Sell citing concerns over free cash flow and his belief that consensus expectations are aggressive. The analyst tonight also upgraded Ingersoll-Rand (IR) to Buy and downgraded Johnson Controls (JCI) to Sell.
12/11/17
STFL
12/11/17
DOWNGRADE
STFL
Hold
Flowserve downgraded to Hold from Buy at Stifel
12/11/17
STFL
12/11/17
DOWNGRADE
Target $43
STFL
Hold
Flowserve downgraded to Hold on lack of near-term catalysts at Stifel
As previously reported, Stifel analyst Nathan Jones downgraded Flowserve to Hold from Buy, saying he sees no near-term catalysts given his expectation of orders being flat to down in Q4. He also sees considerable uncertainty around the timing of margin recovery in its IPD segment. Jones maintains a $43 price target on Flowserve shares.
SHAK Shake Shack
$41.21

1.57 (3.96%)

12/19/17
COWN
12/19/17
NO CHANGE
Target $42
COWN
Market Perform
Shake Shack price target raised to $42 from $36 at Cowen
Cowen analyst Andrew Charles raised his price target on Shake Shack to $42 from $36 as he believes the company would benefit from food delivery, which could drive upside to consensus same-store-sales estimates. Charles said labor and regulatory issues, along with necessary investments to support growth, keep him at a Market Perform rating on the shares.
01/03/18
RHCO
01/03/18
NO CHANGE
Target $60
RHCO
Buy
Shake Shack price target raised to $60 from $50 at SunTrust
SunTrust analyst Jake Bartlett raised his price target on Shake Shack to $60 as part of his "Buy the Tax News" research note on Restaurants. Bartlett says the company is the fastest growing publicly traded restaurant with a 4-year CAGR rate of 44% through 2017. The analyst notes that the company has topped its initial guidance in each of the last 3 years by a wide margin, and believes the initial forecast for FY18 may also prove to be conservative.
12/22/17
JEFF
12/22/17
DOWNGRADE
Target $36
JEFF
Underperform
Shake Shack downgraded to Underperform from Hold at Jefferies
Jefferies analyst Andy Barish downgraded Shake Shack to Underperform with an unchanged price target of $36. The stock closed yesterday up 7c to $46.20. The analyst still believes in the long-term growth opportunity for Shake Shack, but thinks much of that is already discounted in the current valuation. He sees the company's traffic remaining negative in 2018 due to cannibalization, high volumes and a small comp base. Barish calls Shake Shack overvalued following the recent rally in the shares.
12/22/17
12/22/17
DOWNGRADE

On The Fly: Top analyst downgrades
Catch up on today's top analyst downgrades with this list compiled by The Fly: 1. Dynagas LNG (DLNG) downgraded to Hold from Buy at Stifel with analyst Benjamin Nolan saying although the new three-year contract extension with Statoil (STO) improves cash flow visibility, the rates were below expectations and the cash flow gap has widened. 2. Hovnanian (HOV) downgraded to Sell from Neutral at MKM Partners wiht analyst Megan McGrath saying the large positive move up on the heels of its earnings report followed what she viewed as "only a mildly positive quarter." 3. Bojangles (BOJA) was downgraded to Hold from Buy at Jefferies while Wingstop (WING) and Shake Shack (SHAK) were downgraded to Underperform from Hold. 4. WWE (WWE) and Live Nation (LYV) were downgraded to Neutral from Buy at Citi. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
NNDM Nano Dimension
$3.29

0.226 (7.38%)

TODAY'S FREE FLY STORIES

FII

Federated Investors

$24.65

-0.02 (-0.08%)

21:40
12/16/18
12/16
21:40
12/16/18
21:40
Initiation
Federated Investors initiated at Gabelli »

Federated Investors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIII

G-III Apparel

$28.68

-0.29 (-1.00%)

21:37
12/16/18
12/16
21:37
12/16/18
21:37
Upgrade
G-III Apparel rating change at Stifel »

G-III Apparel upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLXT

Calyxt

$9.88

0.4 (4.22%)

21:34
12/16/18
12/16
21:34
12/16/18
21:34
Upgrade
Calyxt rating change at Goldman Sachs »

Goldman upgrades Calyxt…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLXT

Calyxt

$9.88

0.4 (4.22%)

20:23
12/16/18
12/16
20:23
12/16/18
20:23
Upgrade
Calyxt rating change at Goldman Sachs »

Calyxt upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CEQP

Crestwood Equity

$32.29

0.47 (1.48%)

, EQM

EQT Midstream Partners

$46.86

-0.1 (-0.21%)

20:08
12/16/18
12/16
20:08
12/16/18
20:08
Recommendations
Crestwood Equity, EQT Midstream Partners analyst commentary at Goldman Sachs »

Goldman upgrades…

CEQP

Crestwood Equity

$32.29

0.47 (1.48%)

EQM

EQT Midstream Partners

$46.86

-0.1 (-0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ITW

Illinois Tool Works

$131.02

-2.26 (-1.70%)

19:57
12/16/18
12/16
19:57
12/16/18
19:57
Downgrade
Illinois Tool Works rating change at Deutsche Bank »

Illinois Tool Works…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWK

Stanley Black & Decker

$118.36

0.46 (0.39%)

19:57
12/16/18
12/16
19:57
12/16/18
19:57
Upgrade
Stanley Black & Decker rating change at Deutsche Bank »

Stanley Black &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INCY

Incyte

$66.24

-1.04 (-1.55%)

, AET

Aetna

$0.00

(0.00%)

19:31
12/16/18
12/16
19:31
12/16/18
19:31
Hot Stocks
Fly Intel: Top five weekend stock stories »

Catch up on the…

INCY

Incyte

$66.24

-1.04 (-1.55%)

AET

Aetna

$0.00

(0.00%)

ANTM

Anthem

$275.59

-4.93 (-1.76%)

CNC

Centene

$127.55

-5.3 (-3.99%)

CI

Cigna

$205.34

-6.63 (-3.13%)

HNT

Health Net

$0.00

(0.00%)

HUM

Humana

$300.41

-12.09 (-3.87%)

MOH

Molina Healthcare

$131.72

-11.19 (-7.83%)

UNH

UnitedHealth

$265.06

-7.2 (-2.64%)

WCG

WellCare

$236.90

-7.44 (-3.04%)

SNE

Sony

$51.32

-0.88 (-1.69%)

GOOG

Alphabet

$1,041.68

-21.44 (-2.02%)

GOOGL

Alphabet Class A

$1,050.62

-23.36 (-2.18%)

AAPL

Apple

$165.48

-5.45 (-3.19%)

BAC

Bank of America

$24.49

0.1 (0.41%)

BLK

BlackRock

$382.25

-5.29 (-1.37%)

CAT

Caterpillar

$126.78

0.79 (0.63%)

CVX

Chevron

$113.84

-2.15 (-1.85%)

DDAIF

Daimler AG

$0.00

(0.00%)

DAL

Delta Air Lines

$53.50

-0.03 (-0.06%)

ET

Energy Transfer LP

$14.08

-0.5 (-3.43%)

TOL

Toll Brothers

$32.23

-0.4 (-1.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

  • 10

    Jan

  • 29

    Jan

  • 05

    Feb

  • 12

    Feb

  • 19

    Feb

  • 24

    Feb

  • 03

    Mar

EQT

EQT Corporation

$19.40

-0.78 (-3.87%)

18:54
12/16/18
12/16
18:54
12/16/18
18:54
Periodicals
EQT's board to seek meeting with Rice brothers, Reuters reports »

EQT Corporation's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQM

EQT Midstream Partners

$46.86

-0.1 (-0.21%)

, EQGP

EQGP Holdings

$19.94

0.02 (0.10%)

18:31
12/16/18
12/16
18:31
12/16/18
18:31
Downgrade
EQT Midstream Partners, EQGP Holdings rating change at Goldman Sachs »

EQT Midstream downgraded…

EQM

EQT Midstream Partners

$46.86

-0.1 (-0.21%)

EQGP

EQGP Holdings

$19.94

0.02 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CEQP

Crestwood Equity

$32.29

0.47 (1.48%)

18:28
12/16/18
12/16
18:28
12/16/18
18:28
Upgrade
Crestwood Equity rating change at Goldman Sachs »

Crestwood Equity upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INCY

Incyte

$66.24

-1.04 (-1.55%)

17:52
12/16/18
12/16
17:52
12/16/18
17:52
Hot Stocks
Innovent, Incyte announce agreement for three clinical-stage candidates in China »

Incyte and Innovent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

NSANY

Nissan

$0.00

(0.00%)

, RNLSY

Renault

$0.00

(0.00%)

17:14
12/16/18
12/16
17:14
12/16/18
17:14
Periodicals
Renault seeking Nissan shareholder meeting amid Ghosn crisis, Reuters says »

Renault (RNLSY) requested…

NSANY

Nissan

$0.00

(0.00%)

RNLSY

Renault

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

T

AT&T

$30.24

0.33 (1.10%)

, CMCSA

Comcast

$36.32

-0.43 (-1.17%)

16:48
12/16/18
12/16
16:48
12/16/18
16:48
Hot Stocks
Box Office Battle: 'Spider-Verse' wins weekend with $35M »

Sony's (SNE)…

T

AT&T

$30.24

0.33 (1.10%)

CMCSA

Comcast

$36.32

-0.43 (-1.17%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$51.32

-0.88 (-1.69%)

FOX

21st Century Fox

$48.79

-0.09 (-0.18%)

FOXA

21st Century Fox

$49.06

-0.07 (-0.14%)

LGF.A

Lionsgate

$15.59

-0.16 (-1.02%)

DIS

Disney

$112.21

-1.17 (-1.03%)

VIAB

Viacom

$28.56

-0.31 (-1.07%)

VIA

Viacom

$31.23

-0.4 (-1.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 30

    Jan

  • 20

    Mar

ELGX

Endologix

$0.71

0.0232 (3.39%)

16:17
12/16/18
12/16
16:17
12/16/18
16:17
Conference/Events
Endologix to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRPO

Precipio

$0.19

-0.0111 (-5.63%)

16:11
12/16/18
12/16
16:11
12/16/18
16:11
Conference/Events
Precipio to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSB

Mesabi Trust

$25.15

-1.1 (-4.19%)

16:08
12/16/18
12/16
16:08
12/16/18
16:08
Conference/Events
Mesabi Trust to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLNT

Melinta Therapeutics

$1.19

-0.1 (-7.75%)

16:02
12/16/18
12/16
16:02
12/16/18
16:02
Conference/Events
Melinta Therapeutics to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOM

Exxon Mobil

$75.63

-1.32 (-1.72%)

15:55
12/16/18
12/16
15:55
12/16/18
15:55
Periodicals
Exxon Mobil shareholders call for greenhouse gas reduction targets, Reuters says »

A number of institutional…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANTM

Anthem

$275.59

-4.93 (-1.76%)

, CNC

Centene

$127.55

-5.3 (-3.99%)

13:16
12/16/18
12/16
13:16
12/16/18
13:16
Periodicals
Health stocks preparing for market jolt after Obamacare ruling, Bloomberg says »

U.S. health-care stocks…

ANTM

Anthem

$275.59

-4.93 (-1.76%)

CNC

Centene

$127.55

-5.3 (-3.99%)

CI

Cigna

$205.34

-6.63 (-3.13%)

UNH

UnitedHealth

$265.06

-7.2 (-2.64%)

HUM

Humana

$300.41

-12.09 (-3.87%)

WCG

WellCare

$236.90

-7.44 (-3.04%)

MOH

Molina Healthcare

$131.72

-11.19 (-7.83%)

HNT

Health Net

$0.00

(0.00%)

AET

Aetna

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jan

  • 05

    Feb

  • 19

    Feb

JELD

Jeld-Wen

$14.27

-0.46 (-3.12%)

13:02
12/16/18
12/16
13:02
12/16/18
13:02
Hot Stocks
Jeld-Wen announces final ruling in Steves & Sons litigation, to appeal decision »

Jeld-Wen announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATRA

Atara Biotherapeutics

$41.78

-0.74 (-1.74%)

12:55
12/16/18
12/16
12:55
12/16/18
12:55
Hot Stocks
Atara Biotherapeutics presents positive efficacy, safety results for EBV + LMS »

Atara Biotherapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BGNE

BeiGene

$133.95

2.595 (1.98%)

12:41
12/16/18
12/16
12:41
12/16/18
12:41
Hot Stocks
BeiGene announces updated Phase 1A/1B data on tislelizumab »

BeiGene announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JELD

Jeld-Wen

$14.27

-0.46 (-3.12%)

12:35
12/16/18
12/16
12:35
12/16/18
12:35
Hot Stocks
Jeld-Wen ordered to divest Pennsylvania plant to restore competition »

Federal Judge Robert…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMY

Bristol-Myers

$52.11

-1.54 (-2.87%)

, RHHBY

Roche

$0.00

(0.00%)

04:55
12/16/18
12/16
04:55
12/16/18
04:55
Conference/Events
European Society for Medical Oncology (ESMO) to hold a conference »

ESMO Immuno-Oncology…

BMY

Bristol-Myers

$52.11

-1.54 (-2.87%)

RHHBY

Roche

$0.00

(0.00%)

CELG

Celgene

$68.20

-1.55 (-2.22%)

MRK

Merck

$76.50

-1.94 (-2.47%)

PFE

Pfizer

$43.84

-0.71 (-1.59%)

FLDM

Fluidigm

$7.79

-0.39 (-4.77%)

NEO

NeoGenomics

$13.25

-0.18 (-1.34%)

SGEN

Seattle Genetics

$60.46

-0.5 (-0.82%)

TKPYY

Takeda Pharmaceutical

$0.00

(0.00%)

IMV

IMV Inc

$5.65

-0.14 (-2.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

  • 24

    Dec

  • 29

    Dec

  • 11

    Jan

  • 11

    Jan

  • 24

    Jan

  • 16

    Feb

  • 18

    Mar

  • 20

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.